Ganciclovir prophylasis and beta-herpesvirus in renal transplant recipients

Galarraga, M.; Gómez, E.; Oña, Marı́a de; Rodríguez, Azucena; Laurés, A Suárez; Boga, José Antonio; Fernández, José Antonio; Melón, Santiago

doi:10.1111/j.1432-2277.2005.00105.x

Cited by 4 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiviral prophylaxis with ganciclovir or valganciclovir decreased the incidence and HHV‐6 viremia in solid organ transplant patients [Razonable et al, 2005]. Ganciclovir prophylaxis has also been reported to delay and shorten HHV‐6 viremia in renal transplant recipients [Galarraga et al, 2005]. Ganciclovir treatment of CMV disease in liver transplant patients also demonstrated a reduction in concurrent HHV‐6 antigenemia, although the response was slower than that of CMV [Harma et al, 2006].…”

Section: Antiviral Therapymentioning

confidence: 99%

Review, part 1: Human herpesvirus‐6‐basic biology, diagnostic testing, and antiviral efficacy

Flamand

Komaroff

Arbuckle

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

Section: Antiviral Therapymentioning

confidence: 99%

Review, part 1: Human herpesvirus‐6‐basic biology, diagnostic testing, and antiviral efficacy

Flamand

Komaroff

Arbuckle

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

“…Antiviral prophylaxis with ganciclovir or valganciclovir decreased the incidence and HHV-6 viremia in solid organ transplant patients [102]. Ganciclovir prophylaxis has also been reported to delay and shorten HHV-6 viremia in renal transplant recipients [103]. On the other hand, ganciclovir treatment of CMV disease in liver transplant patients demonstrated a decline in concurrent HHV-6 antigenemia, albeit at a slower rate compared with the decline in CMV levels [83].…”

Section: Antiviral Therapymentioning

confidence: 99%

Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review

Lautenschlager

Razonable

2012

Transplant International

View full text Add to dashboard Cite

Summary Human herpesvirus‐6 (HHV‐6), which comprises of HHV‐6A and HHV‐6B, is a common infection after solid organ transplantation. The rate of HHV‐6 reactivation is high, although clinical disease is not common. Only 1% of transplant recipients will develop clinical illness associated with HHV‐6 infection, and most are ascribable to HHV‐6B. Fever, myelosuppression, and end‐organ disease, including hepatitis and encephalitis, have been reported. HHV‐6 has also been associated with various indirect effects, including a higher rate of CMV disease, acute and chronic graft rejection, and opportunistic infection such as invasive fungal disease. All‐cause mortality is increased in solid organ transplant recipients with HHV‐6 infection. HHV‐6 is somewhat unique among human viruses because of its ability to integrate into the host chromosome. The clinical significance of chromosomally integrated HHV‐6 is not yet defined, although a higher rate of bacterial infection and allograft rejection has been suggested. The diagnosis of HHV‐6 is now commonly made using nucleic acid testing for HHV‐6 DNA in clinical samples, but this can be difficult to interpret owing to the common nature of asymptomatic viral reactivation. Treatment of HHV‐6 is indicated in established end‐organ disease such as encephalitis. Foscarnet, ganciclovir, and cidofovir have been used for treatment.

show abstract

Human herpesvirus 6, 7, and 8

Lugo¹,

Zerr²

2021

Pediatric Transplant and Oncology Infectious Diseases

View full text Add to dashboard Cite

Ganciclovir prophylasis and beta-herpesvirus in renal transplant recipients

Cited by 4 publications

References 11 publications

Review, part 1: Human herpesvirus‐6‐basic biology, diagnostic testing, and antiviral efficacy

Review, part 1: Human herpesvirus‐6‐basic biology, diagnostic testing, and antiviral efficacy

Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review

Human herpesvirus 6, 7, and 8

Contact Info

Product

Resources

About